Inflammatory Biomarker Profiling in Elderly Patients With Acute Hip Fracture Treated With Heparins
Authors:
- 2 December 2009
- journal article
- research article
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 16 (1) , 42-50
Abstract
Hip fracture is common in the elderly patients with associated high risk of venous thromboembolic complications. Pathogenic activation results in the generation of various surrogate markers in plasma. This study is designed to identify unique biomarkers in elderly patients with hip fracture using protein chip array enzyme-linked immunosorbent assay (ELISA) methods. Plasma from a randomized hip fracture study (PK-532; n = 341) treated with either enoxaparin (40 mg once daily) or unfractionated heparin (UFH; 5000 IU twice daily) were collected prior to and at 1, 3, 5, and 7 days. A total of 52 samples were analyzed using proteomic surface-enhanced laser desorption/ ionization-time of flight (SELDI-TOF) mass spectrometry to identify unique biomarkers in the molecular weight range of 0 to 150 kd. Twenty-nine healthy volunteer’s and pooled plasma from total hip replacement/total knee replacement patients with a unique biomarker at 11.9 kd were used as quality controls. In the 29 healthy individuals, the biomarker profile did not reveal the presence of any unique peak in comparison to the reference normal human plasma (NHP). Plasma obtained prior to surgery exhibits unique biomarkers in 4 of 52 (7.6%) of the samples. On day 1 postoperatively, 41 of 51 (80.3%) showed a distinct peak at 11.9 kd. On day 3, 43 of 49 (87.8%) patients showed the presence of this biomarker most often at its strongest intensity. In all, 22 of 44 (50%) showed this biomarker on day 5 and 4 of 23 (17.9%) on day 7. C-reactive protein (CRP), tumor necrosis factor α (TNF-α), and serum amyloid A were also increased after surgery. Tissue factor pathway inhibitor (TFPI) antigen levels were increased due to the treatment modalities.Keywords
This publication has 13 references indexed in Scilit:
- Long-term survival after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritisArthritis Research & Therapy, 2005
- Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patientsLaboratory Investigation, 2004
- SELDI‐TOF Serum Profiling for Prognostic and Diagnostic Classification of Breast CancersDisease Markers, 2004
- Identification of Serum Amyloid A Protein As a Potentially Useful Biomarker to Monitor Relapse of Nasopharyngeal Cancer by Serum Proteomic ProfilingClinical Cancer Research, 2004
- Thromboprophylaxis practice patterns in hip fracture surgery patients: experience in Perth, Western AustraliaAnz Journal of Surgery, 2003
- Clinical proteomics: translating benchside promise into bedside realityNature Reviews Drug Discovery, 2002
- ProteinChip ® Clinical Proteomics: Computational Challenges and SolutionsBioTechniques, 2002
- Protein biochips for differential profilingCurrent Opinion in Biotechnology, 2001
- Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease statesCurrent Opinion in Hematology, 2000
- Serum Amyloid A1989